NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.57
-0.43 (-2.26%)
At close: Feb 21, 2025, 4:00 PM
18.55
-0.02 (-0.11%)
After-hours: Feb 21, 2025, 5:48 PM EST
NAMS Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for NAMS stock have an average target of 41.33, with a low estimate of 36 and a high estimate of 48. The average target predicts an increase of 122.56% from the current stock price of 18.57.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NAMS stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +115.40% | Jan 28, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +115.40% | Jan 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $48 | Strong Buy | Reiterates | $48 | +158.48% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $48 | Strong Buy | Initiates | $48 | +158.48% | Dec 30, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $35 → $47 | Buy | Maintains | $35 → $47 | +153.10% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
32.62M
from 14.09M
Increased by 131.53%
Revenue Next Year
9.19M
from 32.62M
Decreased by -71.84%
EPS This Year
-2.12
from -2.15
EPS Next Year
-1.87
from -2.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 40.6M | 38.5M | 63.0M | |||
| Avg | 32.6M | 9.2M | 18.3M | |||
| Low | 13.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 188.4% | 18.0% | 585.9% | |||
| Avg | 131.5% | -71.8% | 99.2% | |||
| Low | -1.9% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.91 | -1.31 | -1.21 | |||
| Avg | -2.12 | -1.87 | -1.74 | |||
| Low | -2.17 | -2.24 | -2.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.